Injecting Wellness: How the Peptide Industry Is Targeting People in Recovery

People in recovery are being deliberately targeted by the peptide industry — and most of us don't even realize it.
In this episode, Anthony breaks down how the influencer ecosystem profits from the exact vulnerability that early recovery creates: the desperate need to feel better, faster. Post-acute withdrawal syndrome is real, the brain genuinely takes time to heal, and predatory actors are filling that gap with products instead of solutions.
He covers what most peptide promoters won't tell you — the regulatory status, the evidence gap, the relapse risk hidden in the behaviors around self-injection and secrecy, and the questions you should be asking before anyone sells you anything in recovery.
This isn't anti-peptide. It's pro-honesty.
Three questions to ask before you try anything being sold in recovery spaces — and what actually worked for Anthony when nothing external did.
---
Topics covered:
• Why people in early recovery are the easiest people to sell to
• How the influencer affiliate model works — and who profits from your discount code
• The regulatory and evidence reality behind the most-promoted peptide compounds
• The relapse risk nobody in the wellness space is talking about
• What peer-reviewed evidence actually requires vs. what's being passed off as proof
• Three questions to ask before anything in recovery gets sold to you
---
If this episode resonated, share it with someone in recovery who's exploring this space. Like, follow, and subscribe — and recovery is simple, not easy.

Mentioned Studies:

BPC-157 — FDA status (unapproved drug, Category 2)

• Operation Supplement Safety (US Dept. of Defense): https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products
• FDA Warning Letter — Summit Research Peptides (Dec 2024): https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024
• FDA Warning Letters search page: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters

BPC-157 — WADA prohibited substance

• USADA: https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/

The human trials problem — only 1 human study out of 544 articles reviewed

• American Journal of Sports Medicine systematic review (Vasireddi et al., 2025 — 544 articles screened, 35 preclinical, 1 clinical): https://journals.sagepub.com/doi/abs/10.1177/15563316251355551
• Arnold's Pump Club plain-language summary of that review: https://arnoldspumpclub.com/blogs/newsletter/bpc-157-the-miracle-peptide-that-s-been-tested-in-only-1-human-trial

The single research group problem

• STAT News / Undark investigation (Feb 2026 — "nearly all data comes from a single research group"): https://www.statnews.com/2026/02/03/bpc-157-peptide-science-safety-regulatory-questions/

NAD therapy — not approved for addiction, evidence is small studies only

• WebMD: https://www.webmd.com/mental-health/addiction/nad-therapy-addiction
• Addiction Center: https://www.addictioncenter.com/treatment/nad-therapy/

PAWS — Post-Acute Withdrawal Syndrome

• Hazelden Betty Ford: https://www.hazeldenbettyford.org/articles/post-acute-withdrawal-syndrome